Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 8/20 | 0.50 |
| ▸ | BCHE | P06276 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30181084 | 1.00 | ACHE (0.50) | ACHEBCHECA1CA2CA4 | |
| Hydrochloric Acid SCHEMBL6448211 | 0.98 | ACHE (0.49) | ACHEBCHECA1CA2CA4 | |
| Hydrochloric Acid SCHEMBL645057 | 0.98 | ACHE (0.49) | ACHEBCHECA1CA2CA4 | |
| SCHEMBL11746926 | 0.85 | DYRK1A (0.51) | ACHEBCHEADORA1KDM4EMEN1 | |
| SCHEMBL15271671 | 0.80 | KMT2A (0.38) | KDM4ENPC1MAPTCYP2C19RAB9A | |
| SCHEMBL10000550 | 0.79 | CYP2A6 (0.40) | ACHEBCHECA1CA2CA4 | |
| SCHEMBL5185079 | 0.76 | ADORA2A (0.41) | ACHEBCHEADORA1ADORA2AKDM4E | |
| SCHEMBL10028036 | 0.75 | MAPT (0.42) | ACHECA1CA2CA4CA6 | |
| SCHEMBL10000565 | 0.74 | CYP2A6 (0.36) | ACHECA1CA2CA4CA6 | |
| SCHEMBL21292583 | 0.74 | ACHE (0.64) | ACHEBCHEADORA1ADORA2ABACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011130677-A1 | INHIBITORS OF CANCER STEM CELLS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2011-10-20 | — | — | WO | claimed |
| US-20250074917-A1 | Preparation and Uses of 7-Azaindenoisoquinolines | PURDUE RESEARCH FOUNDATION | 2025-03-06 | — | — | US | disclosed |
| CN-119497715-A | Preparation and application of 7-aza-indeno isoquinoline | 珀杜研究基金会 | 2025-02-21 | — | — | CN | disclosed |
| EP-4507736-A1 | COMBINATION THERAPY FOR TREATING TROP-2 EXPRESSING CANCERS | GILEAD SCIENCES, INC. (US) | 2025-02-19 | — | — | EP | disclosed |
| US-20240287089-A1 | Preparation and Uses of 7-Azaindenoisoquinolines | PURDUE RESEARCH FOUNDATION (US) | 2024-08-29 | — | — | US | disclosed |
| WO-2024097812-A1 | THERAPY FOR TREATING BLADDER CANCER | GILEAD SCIENCES, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2023215238-A1 | PREPARATION AND USES OF 7-AZAINDENOISOQUINOLINES | PURDUE RESEARCH FOUNDATION (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023201267-A1 | COMBINATION THERAPY FOR TREATING TROP-2 EXPRESSING CANCERS | GILEAD SCIENCES, INC. (US) | 2023-10-19 | — | — | WO | disclosed |
| EP-3480187-B1 | METHOD FOR PREPARING INDENOISOQUINOLINE DERIVATIVES | UNIV NAT TAIWAN NORMAL (TW) | 2023-10-04 | — | — | EP | disclosed |
| US-20230219895-A1 | OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (TOP1) AND TYROSYL-DNA PHOSPHODIESTERASE 1 (TDP1) | SHENZHEN XUHUA BIOTECH CO. LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20030171392-A1 | Substituted indeno[1,2-c]isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2003-09-11 | — | — | US | disclosed |
| EP-1335974-A2 | CRYSTAL COMPOSITIONS COMPRISING TOPOISOMERASE I | Emerald Biostructures Inc. (US) | 2003-08-20 | — | — | EP | disclosed |
| US-20030096833-A1 | Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2003-05-22 | — | — | US | disclosed |
| US-20030096833-A1 | Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2003-05-22 | — | — | US | disclosed |
| US-20030096833-A1 | Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2003-05-22 | — | — | US | disclosed |
| WO-2003020700-A2 | SUBSTITUTED INDENO[1,2-c]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020700-A2 | SUBSTITUTED INDENO[1,2-c]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2002040653-A2 | CHRYSTAL COMPOSITIONS COMPRISING TOPOISOMERASE I | EMERALD BIOSTRUCTURES, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
| US-5597831-A | 6-[X-(2-hydroxyethyl) aminoalkyl]-5,11-dioxo-5,6-dihydro-11-H-indeno[1,2-c]isoquinolines and their use as antineoplastic agents | VUFB A.S (CS) | 1997-01-28 | — | — | US | disclosed |
| EP-0643699-B1 | 6-(2-HYDROXYETHYLAMINOALKYL)-5,11-DIOXO-5,6-DIHYDRO-11H- INDENO[1,2-C]ISOQUINOLINES AND THEIR USE AS ANTINEOPLASTIC AGENTS | VUFB AS (CZ) | 1996-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074917-A1 | Preparation and Uses of 7-Azaindenoisoquinolines | MYC, MYCBP, DNMT1 | ACHE 4790/4885BCHE 4358/4885CA1 4780/4885 |
| US-20030096833-A1 | Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof | UGT1A1, XPO1, IPO7 | ACHE 1046/4885BCHE 1729/4885CA1 4597/4885 |
| US-20030171392-A1 | Substituted indeno[1,2-c]isoquinoline derivatives and methods of use thereof | CYP1B1, UGT1A1, CYP4B1 | ACHE 522/4885BCHE 730/4885CA1 4332/4885 |
| US-20230219895-A1 | OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (TOP1) AND TYROSYL-DNA PHOSPHODIESTERASE 1 (TDP1) | TDP1, TOP1, TOP2A | ACHE 1577/4885BCHE 1903/4885CA1 3228/4885 |
| US-20240287089-A1 | Preparation and Uses of 7-Azaindenoisoquinolines | MYC, MYCBP, DNMT1 | ACHE 4790/4885BCHE 4358/4885CA1 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.